Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers

References

• Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price C. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem.49(10), 1579–1598 (2003).
   PubMedGoogle Scholar
• Zhou BB, Peyton M, HE B et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non small cell lung carcinoma. Cancer Cell10(1–2), 1–12 (2006).
   PubMedGoogle Scholar
• Cook GB, Neamann IE, Goldblatt JL et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno-1 automated system in breast cancer. Anticancer Res.21, 1465–1470 (2001).
   PubMed Web of Science ®Google Scholar
• Schippinger W, Regitnig P, Bauernhofer T et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol. Rep.11, 1131–1136 (2004).
   Google Scholar
• Schondorf T, Hoopmann M, Warm M et al. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastasis receiving trastuzumab therapy predict the clinical course. Clin. Chem.48(8), 1360–1362 (2002).
   PubMedGoogle Scholar
• Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol.20(7), 1800–1808 (2002).
   PubMed Web of Science ®Google Scholar
• Lüftner D, Lüke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin. Biochem.36(4), 233–240 (2003).
   PubMedGoogle Scholar
• Köstler WJ, Schwab B, Singer CF et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res.10, 1618–1624 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer104(2), 257–563 (2005).
   PubMed Web of Science ®Google Scholar
• Ali SM, Esteva FJ, Fornier M et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.24, 18S (2006) (Abstract 500).
   Google Scholar
• Dinocca S, Blot E, Laberje-le Couteulx S et al. Serum level of HER2 extracellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor. Breast Cancer Res. Treat.100(Suppl. 1), S50 (2006) (Abstract 1035).
   Google Scholar
• Esteva FJ, Cheli CD, Fritsche H et al. Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res.7(4), R436–R443 (2005).
   PubMed Web of Science ®Google Scholar
• Fornier MN, Seidman AD, Schwartz MK et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel, association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann. Oncol.16(2), 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Bethune-Volters A, Labroquere M, Guepratte S et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res.24(2C), 1083–1089 (2004).
   PubMedGoogle Scholar
• Tse C, Brault D, Gligorov J, Arien S, Neumann R, Capeau J. Evaluation of serum HER-2, CA15-3, and CEA levels as predictive indicators of therapeutic response in metastatic breast cancer (MBC) treated by trastuzumab-based therapy. Clin. Chim. Acta355(Suppl.), S431 No. WP18.11 (2005).
   Google Scholar
• Kashiwaba M, Inaba T, Wakabayaski G. Serum HER-2/neu extra-cellular domain level predicts clinical response in the patients treated with sequential trastuzumab monotherapy and combination with chemotherapy. Breast Cancer Res. Treat.100(Suppl. 1), S41 (2006) (Abstract 1008).
   Google Scholar
• Blackwell KL, Kaplan EH, Franco SX et al. Determining molecular phenotypes of metastatic (GW572016). Breast Cancer Res. Treat.88(Suppl. 1), 30 (2004) (Abstract 302).
   Google Scholar
• Gomez Hl, Chavez MA, Doval DC et al. Updated biomarker results from a phase 2 randomized study of lapatinib as first-line treatment for patients with ErbB2 amplified advanced or metastatic breast cancer. Breast Cancer Res. Treat.100(Suppl. 68) (2006) (Abstract 1090).
   Google Scholar
• Wright C, Cairns J, Cantwell BJ et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br. J. Cancer65, 271–271 (1992).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Yamauchi H, Broadwater G et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer. Clin. Cancer Res.7, 2703–2711 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol.20, 1467–1472 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol.21(10), 1967–1972 (2003).
   PubMed Web of Science ®Google Scholar
• Sandri MT, Johansson H, Colleoni M et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res.24(2C), 1261–1266 (2004).
   PubMed Web of Science ®Google Scholar
• Colomer R, Liombart-Cussac A, Lluch A et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann. Oncol.15, 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Manouri C, Hall A, Broglio K et al. Kinetics of serum HER-2/neu changes in pateints with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer109, 496–501 (2007).
   PubMedGoogle Scholar
• Yuan P, Xu BH, Chu DT. Correlation between serum HER2 oncoprotein and patients with breast cancer. Clin. Med. Sci. J.19(3), 212–215 (2004).
   Google Scholar
• Fehm T, Gebauer G, Jeger W. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res. Treat.75, 97–106 (2002).
   PubMed Web of Science ®Google Scholar
• Kong SY, Nam BH, Lee KS et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin. Chem.52(8), 1510–1515 (2006).
   PubMedGoogle Scholar
• Zidan J, Dashkovsky I, Stayerman C et al. Comparison of HER2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br. J. Cancer93(5), 552–556 (2005).
   PubMed Web of Science ®Google Scholar
• Edgerton SE, Merkel D, Moore DH, Thor AD. HER2/neu/erbB-b2 status by immunohistochemistry and FISH: clonality and regression with recurrence and metastases. Appl. Immunohistochem. Mol. Morphol.111(3), 214–221 (2003).
   Google Scholar
• Gancberg D, DiLeo A, Cardoso F et al. Comparison of HER-2/neu status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol.13, 1036–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Lueftner DI, Dilk H, Henschke P et al. Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases: results of a 10 year retrospective search in two university institutes of pathology. Breast Cancer Res. Treat.88(Suppl.), 127 (2004) (Abstract 3045).
   Google Scholar
• Regitnig P, Schippinger W, Lindhauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J. Pathol.203(4), 918–926 (2004).
   PubMed Web of Science ®Google Scholar
• Harris LN, Liptcheva V, Broadwater G et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J. Clin. Oncol.19, 1698–1706 (2001).
   PubMed Web of Science ®Google Scholar
• Tse C, Brault D, Gligorov et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin. Chem.51(7), 1093–1101 (2005).
   PubMedGoogle Scholar
• Muller V, Witzel I, Louek HJ et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res. Treat.86(1), 9–18 (2004).
   PubMedGoogle Scholar
• Hoopmann M, Neumann R, Tanasale T, Schondorf T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res.23, 1031–1034 (2003).
   PubMedGoogle Scholar
• Andersen TI, Paus E, Nesland JM et al. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol.34, 499–504 (1995).
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Sevrat J, Albanell J, Rojo F, Arrbas J, Baselga J. Trastuzumab (Herceptin®), a humanized anti-HER2 receptor monoclonal antibody inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res.61, 4744–4749 (2001).
   PubMed Web of Science ®Google Scholar
• Ali SM, Leitzel K, Chinchilli VM et al. Relationship of serum HER-2/neu and serum CA15-3 in patients with metastatic breast cancer. Clin. Chem.48(8), 1314–1320 (2002).
   PubMedGoogle Scholar
• Fehm T, Jager W, Kramer S et al. Prognostic significance of serum HER-2/neu and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res.24, 1987–1992 (2004).
   PubMedGoogle Scholar
• Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price C. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin. Breast Cancer5(2), 105–116 (2004)
   PubMedGoogle Scholar
• Isola JJ, Holli K, Oksa H, Terameto Y, Kallioniemi OP. Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define and aggressive disease course in patients with breast cancer. Cancer73, 652–658 (1994).
   PubMed Web of Science ®Google Scholar
• Solomon DS, Branda R, Ciardiellob F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.19, 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Baron AT, Lafky JM, Boardman CH et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with Stage III or IV epithelial ovarian cancer. J. Cancer Epidemiol. Prev.8, 129–137 (1999).
   Google Scholar
• Carney WP, Burrell M, Morris L, Hamer PJ. Normal levels of serum EGFR and decreases in several cancers. Proc. Am. Assoc. Cancer Res.43, 47 (2003) (Abstract 240).
   Google Scholar
• Gregorc V, Ceresoli GL, Floriani I. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin. Cancer Res.10, 6006–6012 (2004).
   PubMedGoogle Scholar
• Marx J, Leitzel K, Al S et al. Serum EGFR in metastatic breast cancer patients. Proc. Am. Assoc. Cancer Res.21, 436 (2002) (Abstract 1743).
   Google Scholar
• Mueller V, Witzel I, Pantel K, Krenkel S, Luck HJ. Prognostic and predictive impact of soluble epidermal growth factor receptor (EGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res.26, 1479–1488 (2006).
   PubMedGoogle Scholar
• Souder C Leitzel K, Ali SM et al. Serum EGFR/HER-2 predicts poor survival in metastatic breast cancer. Cancer107(10), 2337–2345 (2006).
   PubMedGoogle Scholar
• Pastorek J, Pastorekova S, Gallebaut I. Cloning and characterization of MN, a tumour associated protein with a domain homologous to carbonic anhydrase and a putative helix–loop–helix DNA binding segment. Oncogene9, 2877–2888 (1994).
   PubMed Web of Science ®Google Scholar
• Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family, structure and exon to protein domain relationships. Genomics33, 480–487 (1996).
   PubMed Web of Science ®Google Scholar
• Wykoff C, Beasley N, Watson P et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res.60, 7075–7083 (2000).
   PubMed Web of Science ®Google Scholar
• Svastova E, Hulikova A, Rafajovoa M et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett.577(3), 439–445 (2004).
   PubMed Web of Science ®Google Scholar
• Ivanov S, Liao S, Ivanova A et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol.158(3), 905–919 (2001).
   PubMed Web of Science ®Google Scholar
• Leppiliampi M, Saarnio J, Karttunen T et al. Carbonic anhydrase isozymes IX and XII in gastric tumors. World J. Gastroenterol.9(7), 1398–1403 (2003).
   PubMedGoogle Scholar
• Juhasz M, Chen J, Lendeckel U et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment. Pharmacol. Ther.18, 837–846 (2003).
   PubMed Web of Science ®Google Scholar
• Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. Anticancer Res.26, 1479–1488 (2006).
   PubMedGoogle Scholar
• Zavada J, Zavadova Z, Zat’ovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br. J. Cancer89, 1067–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Sivendran S, Leitzel K, Ali SM et al. Elevated serum MN (carbonic anhydrase) levels in metastatci breast camcer patient sera. Proc. Am. Assoc. Cancer Res.48, 636 (Abstract 2666) (2007).
   Google Scholar